PRF Technologies Ltd. (PRFX) News
Follow PRF Technologies Ltd. (PRFX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
PRF Technologies to Take $250,000 Equity Position in Dotz
PRF Technologies will take a $250,000 equity position in Dotz via an A$2.0 million placement.
EQUITY | Nov 03, 2026, 10:41 PM UTC
L
PRF Technologies Proposes $1.0M GridFeed Sale to Dotz
PRF signed a non-binding term sheet for Dotz to commercialize GridFeed under an exclusive license and acquire the platform for $1.0M. PRF would invest $250K in Dotz’s A$2.0M placement; completion is subject to due dilige
EQUITY | Nov 03, 2026, 09:08 PM UTC
L
Prf Technologies S.H.N. Financial Investments Seeks Special General Meeting At Prf Technologies To Remove Directors, Appoint Three S.H.N. Nominees
PRF Technologies Ltd NASDAQ:PRFX
NEWS | Sep 28, 2026, 11:14 AM UTC
L
S.H.N. Financial Investments Seeks Board Shake-Up at PRF Technologies with 5.716% Stake
S.H.N. Financial Investments Ltd. disclosed a 5.716% stake in PRF Technologies Ltd. through a Schedule 13D. On Sep. 24, 2026, the firm also sent a letter calling for a special meeting of shareholders. The move signals an
NEWS | Sep 24, 2026, 08:39 PM UTC
L
PRFX - PRF Technologies’ GridFeed(TM) to Explore Strategic Growth Opportunity in AI Data Center Power Optimization
PRFX - PRF Technologies’ GridFeed(TM) to Explore Strategic Growth Opportunity in AI Data Center Power Optimization
NEWS | Sep 16, 2026, 01:01 PM UTC
L
PRF Technologies to establish GridFeed as standalone subsidiary
PRFX will establish GridFeed as a standalone subsidiary to pursue strategic alliances for its AI-driven renewable energy trading platform.
EQUITY | Sep 09, 2026, 12:30 PM UTC
M
PRF Technologies FDA clears IND for OcuRing-K Phase II trial
PRF Technologies said the FDA cleared the IND for OcuRing™-K, enabling a U.S. multi-center Phase II trial in cataract surgery. Patient enrollment is expected in the second half of 2026.
REGULATION | Sep 03, 2026, 12:37 PM UTC
L
PRF Technologies 1H Loss $2.8M >PRFX
PRF Technologies 1H Loss $2.8M >PRFX
EQUITY | Sep 03, 2026, 12:33 PM UTC
L
PRFX provides first-half 2026 business update
PRF Technologies issued a first-half 2026 business update.
EQUITY | Sep 03, 2026, 12:32 PM UTC
L
PRFX - PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechn
PRFX - PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI -Driven Energy Platforms
EQUITY | Jul 27, 2026, 12:30 PM UTC
M
PRFX Reports Preclinical Results
PRF Technologies reports expanded preclinical results for PRF-110, showing comparable analgesic efficacy to ZYNRELEF
EQUITY | Jun 25, 2026, 12:30 PM UTC
L
CDNL: Proposes Public Offering
CDNL proposes public offering of common stock
EQUITY | Jun 23, 2026, 09:24 AM UTC
M
CDNL: Proposes Public Offering
CDNL proposes public offering of common stock, among other equity offerings from various companies
EQUITY | Jun 22, 2026, 09:10 PM UTC